Keros Therapeutics, Inc. (KROS)

Market Cap	968.98M
Revenue (ttm)	20.00M
Net Income (ttm)	-78.69M
Shares Out	25.76M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138,236
Open	36.20
Previous Close	36.31
Day's Range	35.68 - 39.02
52-Week Range	24.38 - 68.29
Beta	1.28
Analysts	Buy
Price Target	95.88 (+154.9%)
Earnings Date	Nov 2, 2022

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing smal...

• Industry: Biotechnology
• IPO Date: Apr 8, 2020
• Employees: 97
• Stock Exchange: NASDAQ
• Ticker Symbol: KROS

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is 95.88, which is an increase of 154.86% from the latest price.

Price Target

$95.88

(154.86% upside)

Analyst Consensus: Buy

Stock Forecasts